Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.36
0.309.80%
At close: -
$3.50
0.144.17%
After Hours: 5:17 PM EDT
Comments
Loading...
Relay Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLAY | Benzinga
Relay Therapeutics Inc has a consensus price target of $18.08 based on the ratings of 13 analysts. The high is $29 issued by Raymond James on April 19, 2023. The low is $4 issued by Wells Fargo on April 17, 2025. The 3 most-recent analyst ratings were released by Guggenheim, Wells Fargo, and HC Wainwright & Co. on May 7, 2025, April 17, 2025, and March 7, 2025, respectively. With an average price target of $10 between Guggenheim, Wells Fargo, and HC Wainwright & Co., there's an implied 185.71% upside for Relay Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Wells Fargo
HC Wainwright & Co.
Goldman Sachs
Stifel
1calculated from analyst ratings
Analyst Ratings for Relay Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2025 | Buy Now | 185.71% | Guggenheim | Michael Schmidt68% | $30 → $10 | Maintains | Buy | Get Alert |
| 04/17/2025 | Buy Now | 14.29% | Wells Fargo | — | → $4 | Initiates | → Equal-Weight | Get Alert |
| 03/07/2025 | Buy Now | 357.14% | HC Wainwright & Co. | Robert Burns46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 414.29% | Goldman Sachs | Salveen Richter52% | $20 → $18 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 557.14% | Stifel | Bradley Canino40% | $27 → $23 | Maintains | Buy | Get Alert |
| 01/14/2025 | Buy Now | 357.14% | HC Wainwright & Co. | Robert Burns46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 500% | JMP Securities | Silvan Tuerkcan47% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | 414.29% | Leerink Partners | Christopher Liu50% | $19 → $18 | Maintains | Outperform | Get Alert |
| 12/04/2024 | Buy Now | 357.14% | HC Wainwright & Co. | Robert Burns46% | $20 → $16 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 471.43% | HC Wainwright & Co. | Robert Burns46% | $19 → $20 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | 442.86% | HC Wainwright & Co. | Robert Burns46% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 500% | JMP Securities | Silvan Tuerkcan47% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 700% | Stifel | Bradley Canino40% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 442.86% | HC Wainwright & Co. | Robert Burns46% | $18 → $19 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 585.71% | B of A Securities | Jason Gerberry63% | $20 → $24 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 500% | JP Morgan | Eric Joseph44% | $23 → $21 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 385.71% | Barclays | Peter Lawson43% | $14 → $17 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 471.43% | Goldman Sachs | Salveen Richter52% | → $20 | Reinstates | → Buy | Get Alert |
| 09/10/2024 | Buy Now | 357.14% | Jefferies | Akash Tewari44% | $10.6 → $16 | Upgrade | Hold → Buy | Get Alert |
| 09/10/2024 | Buy Now | — | Oppenheimer | Matthew Biegler39% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/07/2024 | Buy Now | 557.14% | JP Morgan | Eric Joseph44% | $29 → $23 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 585.71% | Oppenheimer | Matthew Biegler39% | $25 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2024 | Buy Now | 300% | Barclays | Peter Lawson43% | $15 → $14 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 500% | JMP Securities | Silvan Tuerkcan47% | $24 → $21 | Maintains | Market Outperform | Get Alert |
| 07/17/2024 | Buy Now | 414.29% | HC Wainwright & Co. | Robert Burns46% | $20 → $18 | Maintains | Buy | Get Alert |
| 06/07/2024 | Buy Now | 471.43% | HC Wainwright & Co. | Robert Burns46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 328.57% | Barclays | Peter Lawson43% | $15 → $15 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/06/2024 | Buy Now | 585.71% | JMP Securities | Silvan Tuerkcan47% | $24 → $24 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/06/2024 | Buy Now | 614.29% | Oppenheimer | Matthew Biegler39% | $33 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 757.14% | Stifel | Bradley Canino40% | $25 → $30 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 385.71% | HC Wainwright & Co. | Robert Burns46% | $19 → $17 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 442.86% | HC Wainwright & Co. | Robert Burns46% | $33 → $19 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 842.86% | HC Wainwright & Co. | Robert Burns46% | $30 → $33 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 757.14% | HC Wainwright & Co. | Robert Burns46% | $32 → $30 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 842.86% | Oppenheimer | Matthew Biegler39% | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 06/09/2023 | Buy Now | 814.29% | HC Wainwright & Co. | Robert Burns46% | $46 → $32 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 585.71% | JMP Securities | Silvan Tuerkcan47% | $28 → $24 | Maintains | Market Outperform | Get Alert |
| 04/20/2023 | Buy Now | 257.14% | Jefferies | Akash Tewari44% | $16 → $12.5 | Upgrade | Underperform → Hold | Get Alert |
| 04/20/2023 | Buy Now | 871.43% | Stifel | Bradley Canino40% | $38 → $34 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 728.57% | JP Morgan | Eric Joseph44% | $42 → $29 | Maintains | Overweight | Get Alert |
| 04/19/2023 | Buy Now | 700% | JMP Securities | Silvan Tuerkcan47% | → $28 | Reiterates | → Market Outperform | Get Alert |
| 04/19/2023 | Buy Now | 728.57% | Raymond James | Dane Leone45% | → $29 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/19/2023 | Buy Now | 328.57% | Barclays | Peter Lawson43% | $23 → $15 | Maintains | Equal-Weight | Get Alert |
| 04/18/2023 | Buy Now | 842.86% | Oppenheimer | Matthew Biegler39% | → $33 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 728.57% | Raymond James | Dane Leone45% | → $29 | Initiates | → Outperform | Get Alert |
| 04/05/2023 | Buy Now | 1100% | JP Morgan | Eric Joseph44% | $45 → $42 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 1214.29% | HC Wainwright & Co. | Robert Burns46% | $43 → $46 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 842.86% | Oppenheimer | Matthew Biegler39% | → $33 | Initiates | → Outperform | Get Alert |
| 01/19/2023 | Buy Now | 700% | JMP Securities | Silvan Tuerkcan47% | $38 → $28 | Maintains | Market Outperform | Get Alert |
| 11/07/2022 | Buy Now | 1128.57% | HC Wainwright & Co. | Robert Burns46% | $50 → $43 | Maintains | Buy | Get Alert |
| 09/30/2022 | Buy Now | 557.14% | Barclays | Peter Lawson43% | → $23 | Initiates | → Equal-Weight | Get Alert |
| 09/14/2022 | Buy Now | 985.71% | JMP Securities | Silvan Tuerkcan47% | $35 → $38 | Maintains | Market Outperform | Get Alert |
| 09/12/2022 | Buy Now | 1328.57% | HC Wainwright & Co. | Robert Burns46% | $46 → $50 | Maintains | Buy | Get Alert |
| 09/02/2022 | Buy Now | 1042.86% | Stifel | Bradley Canino40% | → $40 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 1214.29% | HC Wainwright & Co. | Robert Burns46% | $47 → $46 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Relay Therapeutics (RLAY) stock?
The latest price target for Relay Therapeutics (NASDAQ:RLAY) was reported by Guggenheim on May 7, 2025. The analyst firm set a price target for $10.00 expecting RLAY to rise to within 12 months (a possible 185.71% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
The latest analyst rating for Relay Therapeutics (NASDAQ:RLAY) was provided by Guggenheim, and Relay Therapeutics maintained their buy rating.
When was the last upgrade for Relay Therapeutics (RLAY)?
The last upgrade for Relay Therapeutics Inc happened on September 10, 2024 when Jefferies raised their price target to $16. Jefferies previously had a hold for Relay Therapeutics Inc.
When was the last downgrade for Relay Therapeutics (RLAY)?
The last downgrade for Relay Therapeutics Inc happened on September 10, 2024 when Oppenheimer changed their price target from N/A to N/A for Relay Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $30.00 to $10.00. The current price Relay Therapeutics (RLAY) is trading at is $3.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
